1. Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏
by Nicolas Mounier, Josette Briere, Christian Gisselbrecht, Jean-Francois Emile, Pierre Lederlin, Catherine Sebban, Francoise Berger, Andre Bosly, Pierre Morel, Herve Tilly, Reda Bouabdallah, Felix Reyes, Philippe Gaulard, and Bertrand Coiffier
Blood
Volume 101(11):
June 1, 2003
©2003 by American Society of Hematology

2. The bcl-2 staining patterns.
The bcl-2 staining patterns. The bcl-2 staining patterns for a nodal biopsy specimen (immunoperoxidase method and monoclonal antibody bcl-2). (A) A few positive T cells as positive control (arrows). Tumor cells × 537) are bcl-2–. (B) Almost all tumor cells × 537) are strongly positive for bcl-2 protein expression.
Nicolas Mounier et al. Blood 2003;101:
©2003 by American Society of Hematology

3. OS according to treatment and bcl-2 protein expression.
OS according to treatment and bcl-2 protein expression. (A) OS for patients treated with CHOP. (B) OS for patients treated with R-CHOP. Black lines indicate bcl-2– patients and gray lines indicate bcl-2+ patients.
Nicolas Mounier et al. Blood 2003;101:
©2003 by American Society of Hematology

4. OS according to bcl-2 protein expression and treatment.
OS according to bcl-2 protein expression and treatment. (A) bcl-2– patients. (B) bcl-2+ patients. Black lines indicate patients treated with CHOP and gray lines indicate patients treated with R-CHOP.
Nicolas Mounier et al. Blood 2003;101:
©2003 by American Society of Hematology

5. OS according to aa-IPI and bcl-2 protein expression and treatment. .
Nicolas Mounier et al. Blood 2003;101:
©2003 by American Society of Hematology